TALLINNA FARMAATSIATEHASE AKTSIASELTS
Active Registry code 10093221
AS Tallinn Registered 16 Sep 1996
TALLINNA FARMAATSIATEHASE AKTSIASELTS is a AS based in Tallinn, registry code 10093221, status: active. Main activity: Manufacture of pharmaceutical preparations. According to EMTA, turnover for Q3 2026 was €1 966 989 with 49 employees.
Turnover
1 966 989 €
↓ 5.1% vs Q2 2026
State taxes
315 260 €
↑ 37.0% vs Q2 2026
Labour taxes
323 657 €
↑ 35.2% vs Q2 2026
Employees
49
±0 vs Q2 2026
Q3 2026 · data from the Tax and Customs Board (EMTA)
Position in the industry
- Turnover · Q3 2026 2 mn €above 71% of companiesindustry median 234 187 € · companies in the industry: 12
- Labour taxes per employee 6 605 €above 92% of companiesindustry median 4 573 € · companies in the industry: 12
- Revenue · 2025 6.2 mn €above 91% of companiesindustry median 48 003 € · companies in the industry: 19
- Net profit margin · 2025 7.6 %above 43% of companiesindustry median 9.8 % · companies in the industry: 15
Taxes and turnover
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Quarter | Turnover, € | State taxes, € | Labour taxes, € | Employees |
|---|---|---|---|---|
| Q3 2026 | 1 966 989 | 315 260 | 323 657 | 49 |
| Q2 2026 | 2 071 713 | 230 140 | 239 465 | 49 |
| Q1 2026 | 1 358 752 | 200 416 | 209 176 | 48 |
| Q4 2025 | 1 677 907 | 240 016 | 248 409 | 47 |
| Q3 2025 | 1 752 484 | 319 270 | 328 837 | 49 |
| Q2 2025 | 2 488 003 | 231 860 | 240 346 | 50 |
| Q1 2025 | 1 480 965 | 192 651 | 199 600 | 50 |
| Q4 2024 | 1 969 381 | 315 330 | 326 308 | 47 |
| Q3 2024 | 1 564 491 | 214 166 | 221 900 | 47 |
| Q2 2024 | 2 149 241 | 182 133 | 189 307 | 50 |
| Q1 2024 | 1 540 055 | 181 581 | 188 804 | 50 |
| Q4 2023 | 2 251 599 | 260 991 | 271 713 | 50 |
| Q3 2023 | 1 540 196 | 256 675 | 264 205 | 50 |
| Q2 2023 | 1 818 360 | 160 723 | 167 097 | 51 |
| Q1 2023 | 1 548 087 | 150 770 | 155 881 | 50 |
| Q4 2022 | 2 144 972 | 167 727 | 174 323 | 50 |
| Q3 2022 | 1 550 109 | 271 672 | 280 852 | 52 |
| Q2 2022 | 1 121 217 | 176 582 | 182 733 | 49 |
| Q1 2022 | 1 638 042 | 148 412 | 153 563 | 52 |
Labour taxes per employee per month
2 202 €
Turnover per employee in the quarter
40 143 €
Q3 2026 · calculated from EMTA data
Financials by year
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Year | Revenue, € | Net profit, € | Labour costs, € | Assets, € | Equity, € | Employees |
|---|---|---|---|---|---|---|
| 2025 | 6 159 659 | 466 324 | 3 041 953 | 12 136 457 | 7 942 419 | 44 |
| 2024 | 5 953 245 | 578 465 | 2 936 950 | 11 666 336 | 7 476 095 | 45 |
| 2023 | 5 886 712 | — | — | 11 260 666 | — | 45 |
| 2022 | 5 075 298 | — | — | 10 896 366 | — | 45 |
| 2021 | 5 998 180 | — | — | 11 062 754 | — | 48 |
| 2020 | 5 061 109 | 463 007 | 2 229 615 | 9 707 634 | 5 655 177 | 49 |
| 2019 | 4 717 463 | 541 009 | 2 109 946 | 7 731 394 | 5 192 170 | 48 |
| 2018 | — | — | — | — | — | 45 |
| 2017 | — | — | — | — | — | 45 |
| 2016 | — | — | — | — | — | 44 |
| 2015 | — | — | — | — | — | 50 |
| 2014 | — | — | — | — | — | 59 |
| 2013 | — | — | — | — | — | 62 |
| 2012 | — | — | — | — | — | 60 |
| 2011 | — | — | — | — | — | 59 |
| 2010 | — | — | — | — | — | 59 |
| 2009 | — | — | — | — | — | 64 |
| 2007 | — | — | — | — | — | 75 |
| 2006 | — | — | — | — | — | 71 |
| 2005 | — | — | — | — | — | 71 |
| 2004 | — | — | — | — | — | 71 |
| 2003 | — | — | — | — | — | 92 |
| 2002 | — | — | — | — | — | 138 |
| 2001 | — | — | — | — | — | 178 |
| 2000 | — | — | — | — | — | 209 |
| 1999 | — | — | — | — | — | 218 |
| 1998 | — | — | — | — | — | 302 |
Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.
Financial ratios for 2025
Net profit margin
7.6 %
Net profit / revenue
Return on equity (ROE)
5.9 %
Net profit / equity
Return on assets (ROA)
3.8 %
Net profit / assets
Equity ratio
65.4 %
Equity / assets
Debt ratio
34.6 %
Liabilities / assets
Current ratio
3.10
Current assets / current liabilities
Revenue per employee
139 992 €
Revenue / average full-time employees
Labour cost per employee per month
5 761 €
Labour costs / employees / 12 months (incl. employer taxes)
Annual reports
| Year | Period | Filed | Report | Documents |
|---|---|---|---|---|
| 2025 | 1 Jan 2025 – 31 Dec 2025 | 15 Jun 2026 | Company’s own · audited | e-Äriregister |
| 2024 | 1 Jan 2024 – 31 Dec 2024 | 5 Jun 2025 | Company’s own · audited | e-Äriregister |
| 2023 | 1 Jan 2023 – 31 Dec 2023 | 18 Jun 2024 | Company’s own · audited | e-Äriregister |
| 2022 | 1 Jan 2022 – 31 Dec 2022 | 16 Jun 2023 | Consolidated · audited | e-Äriregister |
| 2021 | 1 Jan 2021 – 31 Dec 2021 | 14 Jun 2022 | Company’s own · audited | e-Äriregister |
| 2020 | 1 Jan 2020 – 31 Dec 2020 | 16 Jun 2021 | Company’s own · audited | e-Äriregister |
| 2019 | 1 Jan 2019 – 31 Dec 2019 | 8 Jun 2020 | Company’s own · audited | e-Äriregister |
Commercial pledges
| No. | Amount | Pledgee | Period |
|---|---|---|---|
| 2 | 3 700 000 EEK | Aktsiaselts Eesti Ühispank | 8 Mar 1999 – in force |
Board
- Nasdaq CSD SEKeeper of the share ledger · since 28 Sep 2017
- Kadri RandveerBoard member · since 30 Oct 2015
Right of representation
Any member of the management board may represent the public limited company in all transactions.
Owners
No owner information.
Beneficial owners
- Janis RomanovskisMember of a senior management body (management or supervisory board) · LVA · since 27 Aug 2025
- Filips LipmansMember of a senior management body (management or supervisory board) · LVA · since 27 Jan 2021
- Anna LipmaneMember of a senior management body (management or supervisory board) · LVA · since 16 Oct 2018
- Kirovs LipmansMember of a senior management body (management or supervisory board) · LVA · since 16 Oct 2018
Founders and other persons
- Erki UsinAudit firm · 3 Nov 2020
- Ernst & Young Baltic ASAudit firm · 3 Nov 2020
- Kirovs LipmansChairman of the supervisory board · 9 Mar 2026
- Filips LipmansSupervisory board member · 31 Jan 2024
- Anna LipmaneSupervisory board member · 2 Feb 2024
- Esindajakonto: SWEDBANK AS CLIENTSShareholder · 875 000 € · 23 Jul 2025
Related companies
Activities (EMTAK)
- 21201Manufacture of pharmaceutical preparations Main
- 47789Retail sale of goods n.e.c.
- 72101Research and experimental development on natural sciences and engineering
Rulings
All rulings (PDF)| Number, date | Title | Deadline | State | Document |
|---|---|---|---|---|
| Ä 10010677 / M11 30 Jan 2018 |
Ruling to correct data outside an entry | 14 Feb 2018 | Deficiencies eliminated 1 Feb 2018 |
|
| Ä 10010677 / 22 16 Jan 2018 |
Amendment entry | In force 16 Jan 2018 |
||
| Ä 10010677 / 21 7 Nov 2017 |
Amendment entry | In force 7 Nov 2017 |
||
| Ä 10010677 / 20 28 Sep 2017 |
Amendment entry | In force 28 Sep 2017 |
||
| Ä 10010677 / 19 12 Sep 2016 |
Amendment entry | In force 12 Sep 2016 |
||
| Ä 10010677 / 18 30 Oct 2015 |
Amendment entry | In force 30 Oct 2015 |
||
| Ä 10010677 / M10 28 Oct 2015 |
Ruling to eliminate deficiencies | 4 Nov 2015 | Deficiencies eliminated 28 Oct 2015 |
|
| Ä 10010677 / M9 11 Feb 2015 |
Ruling to correct data outside an entry | 13 Mar 2015 | Deficiencies eliminated 16 Feb 2015 |
|
| Ä 10010677 / 17 17 Apr 2013 |
Amendment entry | In force 17 Apr 2013 |
||
| Ä 10010677 / M8 10 Apr 2013 |
Ruling to eliminate deficiencies | 10 May 2013 | Deficiencies eliminated 17 Apr 2013 |
|
| Ä 10010677 / 16 7 Aug 2012 |
Amendment entry | In force 7 Aug 2012 |
||
| Ä 10010677 / M7 18 Jul 2012 |
Ruling to eliminate deficiencies | 10 Sep 2012 | In force 18 Jul 2012 |
|
| Ä 10010677 / 15 5 Apr 2012 |
Amendment entry | In force 5 Apr 2012 |
||
| Ä 10010677 / 14 3 Feb 2012 |
Amendment under Commercial Code § 525 (2) | In force 3 Feb 2012 |
||
| Ä 10677 / 13 3 Dec 2008 |
Deletion of activities from the registry card | In force 10 Dec 2008 |
||
| Ä 10677 / M6 28 May 2007 |
Refund of the state fee | In force 28 May 2007 |
||
| Ä 10677 / M5 13 Nov 2006 |
Ruling to be served | In force 13 Nov 2006 |
||
| Ä 10677 / 12 4 May 2006 |
Amendment entry | In force 4 May 2006 |
||
| Ä 10677 / 11 26 Nov 2003 |
Amendment entry | In force | ||
| K 11654 / 6 15 Sep 2003 |
Commercial pledge amended | In force | ||
| K 11654 / 5 12 Sep 2003 |
Commercial pledge deleted | In force | ||
| Ä 10677 / 10 16 Apr 2002 |
Entry decision on the register’s own initiative | In force |
Sources: e-Äriregister and EMTA. Data updated 2 Nov 2026. Open at the source ↗ · Report an error in the data